Novo Nordisk A/S (CPH:NOVO.B)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 1.97T |
| Revenue (ttm) | 303.14B |
| Net Income (ttm) | 104.62B |
| Shares Out | 4.44B |
| EPS (ttm) | 23.48 |
| PE Ratio | 18.92 |
| Forward PE | 16.61 |
| Dividend | 11.40 (2.57%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 9,584,707 |
| Average Volume | 6,370,942 |
| Open | 418.00 |
| Previous Close | 444.30 |
| Day's Range | 406.00 - 443.00 |
| 52-Week Range | 380.00 - 1,033.20 |
| Beta | 0.21 |
| RSI | 47.48 |
| Earnings Date | May 7, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial StatementsNews
Trump calls out weight-loss drugs as target of price-cut push
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices.
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders
Novo Nordisk reports phase 3 data ... Full story available on Benzinga.com
Novo Nordisk Stock Is Slumping Today. Here's Why.
Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.
Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial
Eli Lilly's Zepbound outshines Wegovy in a Phase 3b trial, delivering superior weight loss results.
Novo Nordisk: Nothing Has Changed, Except That It's Cheaper Now
Here’s how much extra weight is lost with Zepbound over Wegovy
A study of two blockbuster weight-loss drugs came out in favor of Eli Lilly over its rival Novo Nordisk.
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the “ most consequential executive order ” in U.S. history, aimed at lowering prescription drug prices....
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
Eli Lilly and Company’s (NYSE: LLY) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S’s (NYSE: NVO) Wegovy in a 72-week head-to-head trial. What Happened: Participants tre...
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
Bagsværd, Denmark, 12 May 2025 – Novo Nordisk today presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya® (somapacitan) was non-inferior to the once-daily growth h...
Eli Lilly's (LLY) Zepbound Outperforms Novo Nordisk's Wegovy in Weight Loss Study
Eli Lilly's (LLY) Zepbound Outperforms Novo Nordisk's Wegovy in Weight Loss Study
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs
Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared bankruptcy this week, citing vastly in...
Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.
The president says big news about drug pricing is coming next week.
Novo Nordisk: It's Not Been This Cheap For Many Years
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Despite setbacks, Novo is actively enhancing market access for Wegovy and partnering with CVS and tel...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons i...
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
Novo Nordisk's CFO says the company is well-placed to respond to an escalation of the global trade war.
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
If short sellers were hoping for a flop from Hims & Hers Health Inc. (NYSE: HIMS), they may want to check their risk management settings. The telehealth disruptor dropped first-quarter earnings after...
Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers
One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk's outlook is brightening.
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are simi...
Ozempic maker Novo Nordisk set for slimmer sales amid surge in copycat weight-loss drugs
Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce replicas.
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 — Streamlining operations and focusing on delivering...